European Commission signs contract with CureVac for access to 405 million doses of its investigational COVID-19 vaccine

The contract on behalf of all EU Member States includes an initial purchase of 225 million doses, of this mRNA-based COVID-19 vaccine that utilises lipid nanoparticles, and also option to request up to a further 180 million doses once efficacy and safety has been proven.

Source:

PharmaTimes